QR Kod

Early increase of CD103 expression on peripheral PD-1+ CD8+ T cells predicts response to nivolumab in advanced esophageal squamous cell carcinoma

Abstract Background Nivolumab has become a standard treatment for advanced or recurrent esophageal squamous cell carcinoma (ESCC). However, reliable blood-based biomarkers predictive of response remain undefined. We investigated dynamic changes in peripheral PD-1+ CD8+ T-cell subsets during nivoluma...

Ful tanımlama

Kaydedildi:
Asıl Yazarlar: Satoko Sumimoto, Tomoki Makino, Shigeto Nakai, Takaomi Hagi, Kota Momose, Kotaro Yamashita, Takuro Saito, Koji Tanaka, Tsuyoshi Takahashi, Yukinori Kurokawa, Kiyokazu Nakajima, Hidetoshi Eguchi, Yuichiro Doki
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Springer 2026-05-01
Seri Bilgileri:Cancer Immunology, Immunotherapy
Konular:
Esophageal cancer
CD103
Nivolumab
T-cell
Online Erişim:https://doi.org/10.1007/s00262-026-04429-5
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller